Skip to main content
SpringerLink
Log in
Book cover

Andrologie pp 349–366Cite as

Therapie mit Testosteron

  • Chapter

Zusammenfassung

Die Hauptindikation für Testosteron ist der Hypogonadismus des Mannes. Eine Übersicht über die weiteren Anwendungsmöglichkeiten liefert Tabelle 15.1. Einigen dieser Verwendungen sind in diesem Buch spezielle Kapitel gewidmet, so dem Einsatz von Testosteron bei konstitutionell verzögerter Pubertät (Kap. 7), in der Senes‑ zenz (Kap. 21),bei der männlichen hormonellen Kontrazeption (Kap. 20.3.3) und bei idiopathischer Infertilität (Kap. 16). Darüber hinaus geht das vorliegende Kapitel auf den Einsatz bei übermäßigem Längenwachstum (Kap. 15.5) und auf den Mißbrauch im Doping bzw. bei Bodybuildern (Kap. 15.6) ein. Aufgrund des erythropoetischen Effektes ist Testosteron auch zur Behandlung der aplastischen und renalen Anämie zugelassen, wurde in diesem Bereich aber seit Einführung des Erythropoetins deutlich zurückgedrängt. Zur Abhandlung dieser Indikation wird der Leser auf Lehrbücher der Inneren Medizin verwiesen.

Alle Pormen des Hypogonadismus, die in den vorhergehenden Kapitein beschrieben wurden und mit einer insuffizienz der Leydig-Zeiien einhergehen, bectürfen einer Therapie mit Testosteron. Auch bei sekundärem Hypogonadismus ist langfristig eine Testosteronsubstitution indiziert die lediglich beim Wunsch nach Zeugungsähigkeit für die Zeitder GnRH oder Gonadotropintherapie unterbrochen wird.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Atkinson L, Chang Y-L, Snyder PJ (1998) Long-term experience with testosterone replacement through scrotal skin. In: Nie-schlag E, Behre HM (eds) Testosterone–action, deficiency, substitution, 2nd ed. Springer, Heidelberg, pp 365–388

    Chapter  Google Scholar 

  • Bagatell CJ, Heimann JR, Rivier JE, Bremner WJ (1994) Effects of endogenous testosterone and estradiol on sexual behaviour in normal young men. J Clin Endocrinol Metab 78: 711–716

    Article  PubMed  CAS  Google Scholar 

  • Bals-Pratsch M, Knuth UA, Yoon YD, Nieschlag E (1986) Trans-dermal testosterone substitution therapy for male hypogonadism. Lancet II: 943–946

    Google Scholar 

  • Barratt-Connor E, von Mühlen DG, Kritz-Silverstein D (1999) Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo study. J Clin Endocrinol Metab 84: 573–577

    Article  Google Scholar 

  • Behre HM, Nieschlag E (1992) Testosterone buciclate (2o-Aet-1) in hypogonadal men: Pharmacokinetics and pharmacodynamies of the new long-acting testosterone ester. J Clin Endocrinol Metab 75: 1204–1210

    Google Scholar 

  • Behre HM, Nieschlag, E. (1998) Comparative pharmacokinetics of testosterone esters. In: Nieschlag E, Behre HM (eds) Testosterone–action, deficiency, substitution, 2nd ed. Springer, Heidelberg, pp 329–348

    Chapter  Google Scholar 

  • Behre HM, Böckers A, Schlingheider A, Nieschlag E (1994a) Sustained suppression of serum LH, FSH testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal man. Clin Endocrinol 40: 241–248

    Article  CAS  Google Scholar 

  • Behre HM, Bohmeyer J, Nieschlag E (1994b) Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal contrals. Clin Endocrinol 40: 341–349

    Article  CAS  Google Scholar 

  • Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82: 2386–2390

    Article  PubMed  CAS  Google Scholar 

  • Behre HM, Abshagen K, Oettel M, Hübler D, Nieschlag E (1999a) Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I-studies. Eur J Endocrinol 140: 414–419

    Article  PubMed  CAS  Google Scholar 

  • Behre HM, von Eckardstein S, Kliesch S, Nieschlag E (1999b) Long-term substitution therapy of hypogonadal men with transscrotal testosterone over seven to ten years. Clin Endocrinol 50: 629–635

    Article  CAS  Google Scholar 

  • Bhasin S (ed) (1998) The therapeutic role of androgens. Baillières Clin Endocrinol Metab 12 (3)

    Google Scholar 

  • Bhasin S, Swerdloff RS, Steiner B, Peterson MA, Meridores T, Galmirin M (1992) A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10–11 weeks in hypogonadal men. J Clin Endocrinol Metab 74: 75–83

    Article  PubMed  CAS  Google Scholar 

  • Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R (1996) The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 335: 1–7

    Article  PubMed  CAS  Google Scholar 

  • Bhasin S, Bross R, Storer TW, Casaburi R (1998) Androgens and muscles. In: Nieschlag E, Behre HM (eds) Testosterone–action, deficiency, substitution, 2nd ed. Springer, Heidelberg, pp 209–227

    Chapter  Google Scholar 

  • Brämswig JH, Nieschlag E, Schellong G (1984) Pituitary-gonadal function in boys after high-dose testosterone treatment of excessively tall stature. Acta Endocrinol 107: 97–103

    PubMed  Google Scholar 

  • Bundesgesundheitsamt: Negativ-Monographien zu anabolen Steroiden: Stanozolol (Bundesanzeiger 1990, Nr. 18), Metenolon (Bundesanzeiger Nr. 48,1990), Oxabolon (Bundesanzeiger Nr.111,1990), Androstanolon (Bundesanzeiger Nr. 240,1990) Nandrolon (Bundesanzeiger Nr. 69, 1993), Clostebol (Bundesanzeiger Nr. 132, 1993), Chlordehydromethyltestosteron (Bundesanzeiger Nr. 72, 1994 )

    Google Scholar 

  • Burris AS, Banks SM, Carter CS, Davidson JM, Sherins RJ (1992) A long-term prospective study of the physiologic and behavioural effects of hormone replacement in untreated hypo-gonadal men. J Androl 13: 297–304

    PubMed  CAS  Google Scholar 

  • Carani C, Bancroft J, Granata A, Del Rio G, Marrama P (1992) Testosterone and erectile function: nocturnal penile tumescence and rigidity, and erectile response to visual erotic stimuli in hypogonadal men. Psychoneuroendocrinol 17: 647–654

    Article  CAS  Google Scholar 

  • Christiansen K (1998) Behavioural correlates of testosterone. In: Nieschlag E, Behre HM (eds) Testosterone–action, deficiency, substitution, 2nd ed. Springer, Heidelberg, pp 107–142

    Chapter  Google Scholar 

  • Clopper RR, Voorhess ML, MacGillivray MH, Lee PA, Mills B (1993) Psychosexual behaviour in hypopituitary men: a controlled comparison of gonadotropin and testosterone replacement. Psychoneuroendocrinol 18: 149–161

    Article  CAS  Google Scholar 

  • Cunningham GR, Hirshkowitz M, Kroenman SG, Karacan I (1990) Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab 70: 792–797

    Article  PubMed  CAS  Google Scholar 

  • de Waal WJ, Vreeburg JTM, Bekkering F, de Jong FH, de Muinck Keizer-Schrama SMPF, Drop SLS, Weber RFA (1995) High-dose testosterone therapy for reduction of final height in constitutionally tall boys: does it influence testicular function in adulthood? Clin Endocrinol 43: 87–95

    Google Scholar 

  • Delanoe D, Fougevrollas B, Meyer L, Thonneau P (1984) Androgenisation of female partners of men on medroxyprogesterone acetate/percutaneous testosterone contraception. Lancet 1: 276

    Article  PubMed  CAS  Google Scholar 

  • Dobs AS, Hoover DR, Chen MC, Allen R (1998) Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. J Endocrinol Metab 83: 33–39

    Article  CAS  Google Scholar 

  • Drop SLS, de Waal J, de Muinck Keizer-Schrama SMPF (1998) Sex steroid treatment of constitutionally tall stature. Endocr Rev 19: 540–558

    CAS  Google Scholar 

  • Eckardstein A (1998) Androgens, cardiovascular risk factors and atherosclerosis. In: Nieschlag E, Behre HM (eds) Testosterone–action, deficiency, substitution, 2nd ed. Springer, Heidelberg, pp 229–257

    Chapter  Google Scholar 

  • Finkelstein JS, Klibanski A (1990) Effects of androgens on bone metabolism. In: Nieschlag E, Behre HM (eds) Testosterone–action, deficiency, substitution. Springer, Heidelberg, pp 204–215

    Chapter  Google Scholar 

  • Gooren LJG (1998) A ten year safety study on the oral androgen testosterone undecanoate. J Andro115: 212–215

    Google Scholar 

  • Hajjar RR, Kaiser FE, Morley JE (1997) Outcomes of long term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 82: 3793–3796

    Article  PubMed  CAS  Google Scholar 

  • Handelsman DJ (1998) Clinical pharmacology of testosterone pellet implants. In: Nieschlag E, Behre HM (eds) Testosterone–action, deficiency, substitution 2nd ed. Springer, Heidelberg, pp 348–364

    Google Scholar 

  • Horowitz M, Wishart JM, O“Loughlin PD, Morris HA, Need AG, Nordin BEC (1992) Osteoporosis and Klinefelter-syndrome. Clin Endocrinol 36: 113–118

    Google Scholar 

  • Jockenhövel F, Vogel E, Reinhardt W, Reinwein D (1997) Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res 2: 293–298

    PubMed  Google Scholar 

  • Jockenhövel F, Bullmann C, Schubert M, Vogel E, Reinhardt W, Reinwein D, Muller-Wieland D, Krone W (1999) Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism 48: 590–596

    Article  PubMed  Google Scholar 

  • Kelleher S, Turner L, Howe C, Conway AJ, Handelsman DJ (1999) Extrusion of testosterone pellets: a randomized controlled clinical study. Clin Endocrinol 51: 469–471

    Article  CAS  Google Scholar 

  • King DS, Sharp RL, Vukovich MD, Brown GA, Reifenrath TA, Uhl NL, Parsons KA (1999) Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial. JAMA 281: 2020–2028

    Article  PubMed  CAS  Google Scholar 

  • Knussmann R, Christansen K, Kannmacher J (1992) Relations between sex hormone levels and character of hair and skin in healthy young men. Am J Phys Anthropol 88: 59–67

    Article  PubMed  CAS  Google Scholar 

  • Knuth UA, Maniera H, Nieschlag E (1989) Anabolic steroids and semen parameters in body builders. Fertil Steril 52: 1041–1047

    PubMed  CAS  Google Scholar 

  • Kochakian CD (ed) (1976) Anabolic androgenic steroids (Handbook of Experimental Pharmacology, Vol. 43 ). Springer, Berlin

    Google Scholar 

  • Kopera H (1985) The history of anabolic steroids and a review of clinical experiences with anabolic steroids. In: Eickelboom FS, van der Vies J (eds) Anabolics in the 8o s. Acta Endocrinol (suppl) 217: 11–18

    Google Scholar 

  • Leifke E, Körner HC, Link TM, Behre HM, Peters PE, Nieschlag E (1998) Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur J Endocrinol 138: 51–58

    Article  PubMed  CAS  Google Scholar 

  • Lemcke B, Zentgraf J, Behre HM, Kliesch S, Nieschlag E (1996) Long-term effects on testicular function of high-dose testosterone treatment for excessively tall stature. J Clin Endocrinol Metab 81: 296–301

    Article  PubMed  CAS  Google Scholar 

  • Meikle AW (1998) A permeation-enhanced non-scrotal testosterone transdermal system for the treatment of male hypogonadism. In: Nieschlag E, Behre HM (eds) Testosterone–action, deficiency, substitution, 2nd ed. Springer, Heidelberg, pp 389–422

    Chapter  Google Scholar 

  • Morales A, Johnston B, Heaton JP, Lundie M (1997) Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J Urol 157: 849–854

    Article  PubMed  CAS  Google Scholar 

  • Nieschlag E (1981) Ist die Anwendung von Methyltestosteron obsolet? Dtsch Med Wschr 106: 1123–1125

    Article  PubMed  CAS  Google Scholar 

  • Nieschlag E (1992) Testosteron, Anabolika and aggressives Verhalten bei Männern. Dtsch Ärztebl 89: 2967–2972

    Google Scholar 

  • Nieschlag E, Behre HM (eds) (1998a) Testosterone - action, deficiency, substitution,znd ed. Springer, Heidelberg

    Google Scholar 

  • Nieschlag E, Behre HM (1998b) Pharmacology and clinical use of testosterone. In: Nieschlag E, Behre HM (eds) Testosterone–action, deficiency, substitution, 2nd ed. Springer, Heidelberg, pp 293–328

    Chapter  Google Scholar 

  • Nieschlag E, Nieschlag S, Behre HM (1993) Life expectancy and testosterone. Nature 366: 215

    Article  PubMed  CAS  Google Scholar 

  • Nieschlag E, Büchter D, von Eckardstein S, Abshagen K, Behre HM (1999) Repeated intramuscular injections of testosterone undecanoate for substitution therapy of hypogonadal men. Clin Endocrinol 51: 757–763

    Article  CAS  Google Scholar 

  • Randall VA (1998) Androgens and hair. In: Nieschlag E, Behre HM (eds) Testosterone–action, deficiency, substitution, 2nd ed. Springer, Heidelberg, pp 169–186

    Chapter  Google Scholar 

  • Salehian B, Wang CH, Alexander G, Davidson T, McDonald V, Berman N, Dudley RE, Ziel F, Swerdloff RS (1995) Pharmacokinetics, bioefficacy and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparision to testosterone enanthate. J Clin Endocrinol Metab 80: 35673575

    Google Scholar 

  • Schaison G, Couzinet B. Percutaneous dihydrotestosterone treatment (1998) In: Nieschlag E, Behre HM (eds) Testosterone–action, deficiency, substitution, 2nd ed. Springer, Heidelberg, pp 423–436

    Chapter  Google Scholar 

  • Schürmeyer T, Nieschlag E (1984) Comparative pharmacokinetics of testosterone enanthate cyclohexanecarboxylate as assessed by serum and saliva testosterone in normal men. Int J Androl 7: 181–187

    Article  PubMed  Google Scholar 

  • Schürmeyer T, Wickings EJ, Freischem CW, Nieschlag E (1983) Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrinol 102: 456–462

    PubMed  Google Scholar 

  • Schürmeyer T, Jung K, Nieschlag E (1984) The effect of a ssoo km run on testicular, adrenal and thyroid hormones. Int J Androl 7: 276–282

    Article  PubMed  Google Scholar 

  • Snyder PJ, Peachey H, Hannoush P et al. (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84x966–1972

    Google Scholar 

  • Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, Swerdloff RS (1996) Testosterone replacement therapy improves mood in hypo-gonadal men–a clinical research center study. J Endocrinol Metab 81: 3578–3583

    Article  CAS  Google Scholar 

  • Wang C, Berman N, Longstreth JA, Chnapoco B, Hull L, Steiner B, Faulkner S, Dudley RE, Swerdloff RS (2000) Pharmacokinetics of transdermal testosterone gel in hypogonadel men: application of gel at one site versus four sites. J Clin Endocrinol Metab 85: 964–969

    Article  PubMed  CAS  Google Scholar 

  • Wilson JD (1988) Androgen abuse by athletes. Endocr Rev 9:181-

    Google Scholar 

  • World Health Organization, Nieschlag E, Wang CH, Handelsman DJ, Swerdloff RS, Wu FCW, Einer-Jensen N, Khanna J, Waites GMH (eds) (1992) Guidelines for the use of androgens. WHO, Geneva

    Google Scholar 

  • Yu YM, Punyasavatsu N, Elder D, D’Ercole AJ (1999) Sexual development in a two-year-old boy induced by topical exposure to testosterone. Pediatrics 104: 23

    Article  Google Scholar 

  • Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ (1998) A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl 19: 761–768

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. E. Nieschlag
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. M. Behre
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Reproduktionsmedizin, Westfälischen Wilhelms-Universität, Domagkstr. 11, D-48129, Münster, Deutschland

    Eberhard Nieschlag FRCP

  2. Zentrum für Frauenheilkunde, Westfälischen Wilhelms-Universität, Albert-Schweitzer-Str. 33, D-48129, Münster, Deutschland

    Hermann M. Behre

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Nieschlag, E., Behre, H.M. (2000). Therapie mit Testosteron. In: Nieschlag, E., Behre, H.M. (eds) Andrologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-05739-1_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-05739-1_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-05740-7

  • Online ISBN: 978-3-662-05739-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation